Silvestre Vicent

Instituto de Salud Carlos III — Spain

Biochemistry, Genetics and Molecular Biology · Life Sciences

34h-index3.5kcitations185works1.72yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

RNA modifications and cancer(41), Cancer Cells and Metastasis(36), Pancreatic and Hepatic Oncology Research(27), Lung Cancer Treatments and Mutations(25), Cancer, Hypoxia, and Metabolism(19)

Publications184 total

Figure S1 from LAMC2 Regulates Key Transcriptional and Targetable Effectors to Support Pancreatic Cancer Growth
2025Open Access
Figure S4 from LAMC2 Regulates Key Transcriptional and Targetable Effectors to Support Pancreatic Cancer Growth
2025Open Access
Figure S2 from LAMC2 Regulates Key Transcriptional and Targetable Effectors to Support Pancreatic Cancer Growth
2025Open Access
Figure S3 from LAMC2 Regulates Key Transcriptional and Targetable Effectors to Support Pancreatic Cancer Growth
2025Open Access
Figure S5 from LAMC2 Regulates Key Transcriptional and Targetable Effectors to Support Pancreatic Cancer Growth
2025Open Access
Figure S7 from LAMC2 Regulates Key Transcriptional and Targetable Effectors to Support Pancreatic Cancer Growth
2025Open Access
Figure S6 from LAMC2 Regulates Key Transcriptional and Targetable Effectors to Support Pancreatic Cancer Growth
2025Open Access
Supplementary Data DS1 from LAMC2 Regulates Key Transcriptional and Targetable Effectors to Support Pancreatic Cancer Growth
2025Open Access
Supplementary Tables from Dasatinib Remodels the Tumor Microenvironment and Sensitizes Small Cell Lung Cancer to Immunotherapy
2025Open Access
Supplementary Figure 4 from Dasatinib Remodels the Tumor Microenvironment and Sensitizes Small Cell Lung Cancer to Immunotherapy
2025Open Access
Supplementary Figure 5 from Dasatinib Remodels the Tumor Microenvironment and Sensitizes Small Cell Lung Cancer to Immunotherapy
2025Open Access
Supplementary Figure 9 from Dasatinib Remodels the Tumor Microenvironment and Sensitizes Small Cell Lung Cancer to Immunotherapy
2025Open Access
Supplementary Figure 7 from Dasatinib Remodels the Tumor Microenvironment and Sensitizes Small Cell Lung Cancer to Immunotherapy
2025Open Access
Supplementary Figure 3 from Dasatinib Remodels the Tumor Microenvironment and Sensitizes Small Cell Lung Cancer to Immunotherapy
2025Open Access
Supplementary Figure 6 from Dasatinib Remodels the Tumor Microenvironment and Sensitizes Small Cell Lung Cancer to Immunotherapy
2025Open Access
Supplementary Figure 8 from Dasatinib Remodels the Tumor Microenvironment and Sensitizes Small Cell Lung Cancer to Immunotherapy
2025Open Access
Supplementary Figure 1 from Dasatinib Remodels the Tumor Microenvironment and Sensitizes Small Cell Lung Cancer to Immunotherapy
2025Open Access
Supplementary Figure 2 from Dasatinib Remodels the Tumor Microenvironment and Sensitizes Small Cell Lung Cancer to Immunotherapy
2025Open Access
Data from Dasatinib Remodels the Tumor Microenvironment and Sensitizes Small Cell Lung Cancer to Immunotherapy
2025Open Access
Dasatinib Remodels the Tumor Microenvironment and Sensitizes Small Cell Lung Cancer to Immunotherapy
Cancer Research·2025· 4 cited
page 1 of 10Next →

Frequent Co-authors

Fernando Lecanda(21), Luis M. Montuenga(14), Elizabeth Guruceaga(14), Karmele Valencia(11), Rubén Pı́o(9), Haritz Moreno(8), Mariano Ponz‐Sarvisé(8), E. Alejandro Sweet‐Cordero(8), Ignacio Gil‐Bazo(7), Daniel Ajona(7), Carolina Zandueta(7), Irati Macaya(7), Inés López(6), Sergio Ortiz‐Espinosa(6), Adrián Vallejo(6), Naiara Perurena(6), Marta Román(5), Susana Martínez-Canarias(5), Leanne C. Sayles(5), Purvesh Khatri(5)